Medicare Claims Put RSV Vaccine Protection Above 80% in the First Season on the Market

Listen to this Articleby George Padron - Last Updated: Sep 26, 2026

Both respiratory syncytial virus vaccines approved in 2023 cut RSV-related hospitalization by roughly 82% and RSV-related death by 85% among Medicare fee-for-service beneficiaries during the 2023-2024 season, according to an FDA-led cohort study published in JAMA Network Open. Protection held steady across every age band from 65 upward and remained substantial in immunocompromised patients.

Investigators at the FDA Center for Biologics Evaluation and Research, working with Acumen LLC under an interagency agreement with the Centers for Medicare & Medicaid Services, followed 14,819,226 community-dwelling beneficiaries aged 65 years or older from August 6, 2023, through March 2, 2024. Long-term care residents, hospice patients, and those receiving dialysis were excluded. By the study's end, 13.9% had received the GSK adjuvanted vaccine (RSVPreF3+AS01) and 6.4% the Pfizer vaccine (RSVpreF). Vaccinated beneficiaries were notably less likely to be dually eligible for Medicaid (4.2% vs 12.9%), lived in less deprived areas, and were far more likely to have had a prior influenza shot (90.6% vs 56.4%) or COVID-19 vaccination (77.9% vs 33.9%).

Using marginal structural models with inverse probability weighting and a doubly robust outcome model, the team estimated overall vaccine effectiveness of 81.8% (95% CI, 80.0%-83.4%) against RSV-related hospitalization and 85.0% (95% CI, 75.1%-90.9%) against RSV-related death. By brand, effectiveness against hospitalization was 79.9% for the GSK product and 85.1% for the Pfizer product. Among immunocompromised beneficiaries, effectiveness was 72.2% overall, with brand estimates of 66.4% and 81.1%, respectively. Restricting the analysis to beneficiaries with prior influenza vaccination, a proxy for health-seeking behavior, produced nearly identical results, and alternate RSV circulation thresholds did not shift the estimates. Fewer than 20 RSV-related deaths occurred among roughly 3 million vaccinated individuals.

The authors note that this is the first study, to their knowledge, to estimate effectiveness against RSV-related death, made possible by the size of the Medicare population. Limitations include the absence of laboratory-confirmed diagnoses, likely underreporting of RSV in claims, and exclusion of adults aged 60 to 64 years. The Moderna vaccine was not included because it was approved after the study window. The authors conclude that the findings provide clinical evidence of RSV vaccine effectiveness in the first year after approval.

 


References

JAMA Netw Open Respiratory syncytial virus vaccine effectiveness among US older adults, 2023-2024 season


Related Articles

Only Healthcare Today Covering Clinical Healthcare, Access and Cost

Only Healthcare Today
Covering Clinical Healthcare, Access and Cost

1 Hewitt Square, Suite 139
East Northport, NY 11731

Who We Are


About Us Editorial Policy Contributors & Partners

Connect


Contact Us Work With Us Advertising Terms of Use Privacy Policy